Impact of Lack of Access to Immunotherapy on Survival in Stage IV Non–Small Cell Lung Cancer: A Multicenter Retrospective Study From Lebanon
JCO Global Oncology · 2026-07 · 12 (7)
DOI: 10.1200/go-26-00203 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JCO Global Oncology, 2026-07. Verfasst von Mohammad Hassan Hodroj und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Naef K. Basile Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immunotherapy. Die Arbeit nennt 18 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Lung cancer remains the leading cause of cancer-related mortality worldwide. Immune checkpoint inhibitors (ICIs) have become the standard of care for stage IV non–small cell lung cancer (NSCLC). In 2021, Lebanon experienced a severe economic collapse that resulted in major shortages of immunotherapy and treatment interruptions. The aim of this study was to explore the potential impact of immunotherapy shortage on progression-free survival (PFS). METHODS This retrospective multicenter study included patients with newly diagnosed stage IV NSCLC treated between January 2019 and December 2020 (control group) and between October 2021 and December 2022 (crisis group). The primary end point was PFS, defined from treatment initiation to progression according to RECIST 1.1 criteria or death. Kaplan-Meier survival curves were generated, and differences were assessed using log-rank test. RESULTS A total of 500 medical records were reviewed; 158 eligible patients were included (73 control, 85 crisis). The total cohort included 60.8% men with a mean age of 69.7 years. Among immunotherapy recipients, 44.0% received full-dose therapy (dose density ratio = 1.0), 41.4% received 50%-99% of standard dose (dose density ratio = 0.50-0.99), and 14.7% received
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Hematology and Oncology, Naef K. Basile Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon.
- Division of Hematology and Oncology, Lebanese American University Medical Center, Beirut, Lebanon.
- Division of Hematology and Oncology, Saint Georges University Medical Center, Beirut, Lebanon.
- Division of Hematology and Oncology, University Medical Center Hôtel-Dieu De France-Saint Joseph University of Beirut, Beirut, Lebanon.
- Division of Hematology and Oncology, Hammoud Hospital University Medical Center, Beirut, Lebanon.
ORCID-Profile: Mohammad Hassan Hodroj, Hasan Numan, Firas Rammal, Ali Ghais, Maya Charafeddine, Cendrella Bou Orm, Samah Seif, Hady Ghanem, Malek Safa, Arafat Tfayli
Zitieren
APA
Hodroj, M. H., Numan, H., El-Halabi, L., Rammal, F., Ghais, A., Tfayli, R., Orm, A. B., Charafeddine, M., Orm, C. B., Haddad, K., Seif, S., Ghanem, H., El-Hachem, G., El Karak, F., Farhat, F., Safa, M., Khuri, F. R., & Tfayli, A. (2026). Impact of Lack of Access to Immunotherapy on Survival in Stage IV Non–Small Cell Lung Cancer: A Multicenter Retrospective Study From Lebanon. JCO Global Oncology, 12(7). https://doi.org/10.1200/go-26-00203
Vancouver
Hodroj MH, Numan H, El-Halabi L, Rammal F, Ghais A, Tfayli R, et al. Impact of Lack of Access to Immunotherapy on Survival in Stage IV Non–Small Cell Lung Cancer: A Multicenter Retrospective Study From Lebanon. JCO Global Oncology. 2026;12(7). doi:10.1200/go-26-00203
BibTeX
@article{Hodroj2026,
author = {Hodroj, Mohammad Hassan and Numan, Hasan and El-Halabi, Laura and Rammal, Firas and Ghais, Ali and Tfayli, Rami and Orm, Abdallah Bou and Charafeddine, Maya and Orm, Cendrella Bou and Haddad, Karim and Seif, Samah and Ghanem, Hady and El-Hachem, Georges and El Karak, Fadi and Farhat, Fadi and Safa, Malek and Khuri, Fadlo R and Tfayli, Arafat},
title = {Impact of Lack of Access to Immunotherapy on Survival in Stage IV Non–Small Cell Lung Cancer: A Multicenter Retrospective Study From Lebanon},
journal = {JCO Global Oncology},
year = {2026},
volume = {12},
number = {7},
doi = {10.1200/go-26-00203}
}
EUVIMED